• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $BNGO

    Bionano Genomics Inc.

    Subscribe to $BNGO
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes. Its Saphyr system includes an instrument, chip consumables, reagents, a suite of data analysis tools, and genome analysis services for researchers to evaluate optical genome mapping data. The company's Bionano prep kits and labeling kits provide the reagents and protocols needed to extract and label ultra-high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. Bionano Genomics, Inc. has a procurement and collaboration agreement with NuProbe, Inc. for research and product development in the fields of reproductive health and oncology liquid biopsies. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

    IPO Year: 2018

    Exchange: NASDAQ

    Website: bionanogenomics.com

    Peers

    $PACB

    Recent Analyst Ratings for Bionano Genomics Inc.

    DatePrice TargetRatingAnalyst
    11/15/2024Buy → Neutral
    Ladenburg Thalmann
    9/10/2024Buy → Neutral
    BTIG Research
    1/5/2023$4.00Sector Outperform
    Scotiabank
    12/12/2022$3.50Buy
    BTIG Research
    7/18/2022$12.00Outperform
    Oppenheimer
    See more ratings

    Bionano Genomics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Twomey Christopher J

      4 - Bionano Genomics, Inc. (0001411690) (Issuer)

      6/12/25 4:51:11 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Director Vuori Kristiina Md

      4 - Bionano Genomics, Inc. (0001411690) (Issuer)

      6/12/25 4:50:58 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Director Linney Yvonne

      4 - Bionano Genomics, Inc. (0001411690) (Issuer)

      6/12/25 4:50:47 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Director Luderer Albert

      4 - Bionano Genomics, Inc. (0001411690) (Issuer)

      6/12/25 4:50:37 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Director Barker David L

      4 - Bionano Genomics, Inc. (0001411690) (Issuer)

      6/12/25 4:50:28 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Director Mamuszka Hannah

      4 - Bionano Genomics, Inc. (0001411690) (Issuer)

      6/12/25 4:50:13 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Director Rajkovic Aleksandar

      4 - Bionano Genomics, Inc. (0001411690) (Issuer)

      6/12/25 4:50:03 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Operating Officer Oldakowski Mark covered exercise/tax liability with 27 shares, decreasing direct ownership by 3% to 974 units (SEC Form 4)

      4 - Bionano Genomics, Inc. (0001411690) (Issuer)

      6/3/25 6:59:01 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Principal Accounting Officer Adamchak Mark covered exercise/tax liability with 7 shares, decreasing direct ownership by 3% to 263 units (SEC Form 4)

      4 - Bionano Genomics, Inc. (0001411690) (Issuer)

      6/3/25 6:58:51 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Medical Officer Chaubey Alka covered exercise/tax liability with 24 shares, decreasing direct ownership by 3% to 713 units (SEC Form 4)

      4 - Bionano Genomics, Inc. (0001411690) (Issuer)

      6/3/25 6:58:41 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials